Press releases
- Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
- Veracyte to Participate in Upcoming Investor Conferences
- Veracyte Announces First Quarter 2024 Financial Results
- 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
More ▼
Key statistics
As of last trade Veracyte Inc (12V:DUS) traded at 19.10, 9.14% above its 52-week low of 17.50, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.00 |
---|---|
High | 19.10 |
Low | 19.00 |
Bid | 19.10 |
Offer | 19.50 |
Previous close | 19.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | 76.45m |
Free float | 75.80m |
P/E (TTM) | -- |
Market cap | 1.59bn USD |
EPS (TTM) | -0.9346 USD |
Data delayed at least 15 minutes, as of May 24 2024 11:30 BST.
More ▼